Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-05

Study Completion Date

2018-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a randomized, double-blind, placebo-controlled, three-period cross-over study in approximately 54 subjects with asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

NCT00927901

Asthma

COMPLETED PHASE2

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

NCT02892019

Asthma

COMPLETED PHASE2

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529

Asthma

COMPLETED PHASE3

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

NCT00624702

Asthma

COMPLETED PHASE1

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled, three-period cross-over study in asthma patients. The study will consist of a screening epoch, followed by a treatment epoch which consists of three treatment periods, and will conclude with an end of study epoch.

Each subject will be assigned to 1 of 6 treatment sequences and will sequentially receive the investigational products and placebo during the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

A-B-C

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Sequence 2

B-C-A

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Sequence 3

C-A-B

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Sequence 4

A-C-B

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Sequence 5

B-A-C

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Sequence 6

C-B-A

Group Type EXPERIMENTAL

Indacaterol maleate

Intervention Type DRUG

150 μg via Concept1 device

Indacaterol acetate

Intervention Type DRUG

150 μg via Concept1 device

Placebo

Intervention Type DRUG

Capsule containing no active ingredients delivered via Concept1 device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Indacaterol maleate

150 μg via Concept1 device

Intervention Type DRUG

Indacaterol acetate

150 μg via Concept1 device

Intervention Type DRUG

Placebo

Capsule containing no active ingredients delivered via Concept1 device

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

A B C

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients aged ≥ 18 and above
* Patients with a documented physician diagnosis of asthma for a period of at least 1 year prior to screening and who additionally meet the following criteria:

Patients receiving daily treatment with an inhaled corticosteroid up to the maximum dose per day (as indicated in the package leaflet), on a stable regimen for at least 4 weeks prior to screening.

* Pre-bronchodilator FEV1 ≥ 50 % and ≤ 90% of the predicted normal value for the patient during screening.
* Patients who demonstrate an increase in FEV1 of ≥ 12% and ≥ 200 mL after administration of 400 μg salbutamol/360 μg albuterol (or equivalent dose) at screening.
* Subjects must weigh at least 50 kg at screening to participate in the study, and must have a body mass index (BMI) within the range of 18 to 40 kg/m2.

Exclusion Criteria

-Contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs, drugs of a similar class, or any component thereof: Sympathomimetic amines / adrenoceptor agonist agents Lactose or any of the other excipients of the study drug (including patients with history of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption)

* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of screening.
* Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to screening.
* Patients with a history of chronic lung diseases other than asthma
* Patients who have a decline in PEF from the reference PEF (taken at screening) of ≥30% for 5 of 6 consecutive scheduled PEF readings (readings taken at morning and evening) during at least 3 days of screening epoch prior to randomization.
* Patients who require the use of ≥12 puffs / 24 hours of rescue medication for 48 hours (over two consecutive days) during screening prior to randomization.
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
* Patients with Type I diabetes or uncontrolled Type II diabetes (HbA1c \> 9%) at screening.
* Current smokers (urine cotinine \> than the laboratory's lowest level of quantification (LoQ of 500 ng/mL or lower)) and patients who have smoked or inhaled tobacco products within the 6 month period prior to screening, or who have a smoking history of greater than 10 pack years (Note: 1 pack is equivalent to 20 cigarettes. 10 pack years = 1 pack /day x 10 yrs., or ½ pack/day x 20 yrs.).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No